The Combined Use of Disease Activity and Infliximab Serum Trough Concentrations for Early Prediction of (Non-)Response to Infliximab in Rheumatoid Arthritis

British Journal of Clinical Pharmacology - United Kingdom
doi 10.1111/bcp.12142